

Supporting Information

Carborane as an Alternative Efficient Hydrophobic Tag for Protein Degradation

Yasunobu Asawa,^a Kei Nishida,^b Kazuki Kawai,^a Kiyotaka Domae,^a Hyun Seung Ban,^c Akihiro Kitazaki,^d Hiroya Asami,^d Jun-Ya Kohno,^d Satoshi Okada,^{a,c} Hiraku Tokuma,^a Daisuke Sakano,^a Shoen Kume,^a Masaru Tanaka,^b Hiroyuki Nakamura^{a,e,*}

^a School of Life Science and Technology, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan

^b Institute for Materials Chemistry and Engineering, Kyushu University, 744 Motoooka, Nishi-ku, Fukuoka, 819-0395, Japan

^c Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, South Korea

^d Department of Chemistry, Faculty of Science, Gakushuin University, 1-5-1 Mejiro, Toshima-ku, Tokyo 171-8588, Japan

^e Laboratory for Chemistry and Life Science, Institute of Innovative Research, Tokyo Institute of Technology, 4259 Nagatsuta-cho, Midori-ku, Yokohama 226-8503, Japan

*E-mail: hiro@res.titech.ac.jp

Content


1. Synthesis of Carborane Tags	S2
General	S2
Synthesis of compounds 1~5 and MIC	S2~S5
2. Biology	S6
Figure S1. Flow cytometric analysis of HA–HaloTag2-EGFP levels in Flp-In 293 cells	S6
Table S1. Condition of electroporation for FITC-BSA	S6
Figure S2. Histograms and Mean fluorescence intensity of FITC-BSA in LNCaP cells	S7
Figure S4. Stability of compound 1 and 2	S8
3. References	S9
4. Spectra data of compounds 3~7 and MIC	S10~S15

1. Synthesis of Carborane Tags

General


NMR spectra were recorded on a Bruker biospin AVANCE II (400 MHz for ^1H , 100 MHz for ^{13}C) or a Bruker biospin AVANCE III (500 MHz for ^1H , 125 MHz for ^{13}C , 470 MHz for ^{11}B) instrument in the indicated solvent. Chemical shifts are reported in units per million (ppm) relative to the signal (0.00 ppm) for internal tetramethylsilane solutions in CDCl_3 (7.26 ppm for ^1H , 77.16 ppm for ^{13}C). Multiplicities are reported using the following abbreviations: s; singlet, d; doublet, dd; doublet of doublets, t; triplet, q; quartet, m; multiplet, br; broad, J; coupling constants in Hertz. Mass spectra were measured using a JMS-700 Mstation. IR spectra were recorded on a JASCO FT/IR-4100 spectrometer. IR spectrum was recorded on a JASCO Corporation FT/IR-4100 FT-IR Spectrometer. ATR PRO ONE was attached to the FT/IR-4100 in measuring solid IR spectroscopy by single reflection attenuated total reflection. Only the strongest and/or structurally important peaks were reported as the IR data given in cm^{-1} . High-resolution mass spectra (HRMS) were recorded on a Bruker ESI-TOF-MS (microTOF II). All reactions were monitored by thin-layer chromatography carried out on 0.2 mm E. Merck silica gel plates (60F-254) with UV light (254 nm) and were visualized using Hanessian's stain solution. Column chromatography was performed on Silica Gel 60 N, purchased from Fuji Silysia Chemical Ltd. HyT13, HyT55 and 2-(2-((6-chlorohexyl)oxy)ethoxy)-ethanamine (HaloTag linker **6**) were known and synthesized according to the literature procedures.^{1,2}

Synthesis of 1-carboxyl-1,7-dicarba-*closo*-dodecaborane (**3**)




To a solution of *m*-carborane (488 mg, 3.38 mmol) in THF (15 mL), was slowly added *n*-BuLi 1.6 M solution in hexane (2 mL, 3.21 mmol) at $-78\text{ }^{\circ}\text{C}$. After the resulting mixture was stirred room temperature under argon atmosphere for 1 h, the CO_2 balloon was attached. Then, the resulting mixture was stirred at room temperature CO_2 atmosphere for 3 h. After that, the reaction mixture was concentrated under pressure. The resulting mixture was added and Hexane after which the product was partitioned between the aqueous and organic layers. The aqueous layer was washed with Hexane. Then, the aqueous layer was added 6 M HCl and Hexane after which the product was partitioned between the aqueous and organic layers. The aqueous layer was extracted with Hexane and combined organic layers were dried over sodium sulfate and concentrated under vacuum to afford **3** (444 mg, 2.36 mmol, 74%). ^1H NMR (400 MHz, CDCl_3): δ 3.03 (brs, 1H), 4.10-1.60 (m, 10H). This spectrum is consistent with the reported values.³

Synthesis of *N*-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-1,7-dicarba-*closo*-dodecaborane-1-carboxamide (**1**)




To a solution of **3** (6.1 mg, 0.031 mmol.) and HaloTag linker **6** (40 mg, 1.78 mmol) in DCM (1.2 mL) were added HOBt (15 mg, 0.11 mmol) and EDCI (17.9 mg, 0.093 mmol). After the reaction mixture was cooled to 0 °C, was slowly added DIEA (40 μ L, 3.09 mmol). The resulting mixture was stirred at room temperature for 8.5 h and quenched with H₂O. The mixture was extracted twice with ethyl acetate and the combined extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by column chromatography on silica gel (70% EtOAc in Hexane) afforded **1** as slight yellow oil (7.5 mg, 0.019 mmol, 60%). ¹H NMR (400 MHz, CDCl₃) δ 6.32 (bs, 1H), 3.61-1.59 (m, 2H), 3.57-3.51 (m, 6H), 3.47 (t, *J* = 6.7 Hz, 2H), 3.39 (q, *J* = 5.2 Hz, 2H), 3.02 (s, 1H), 2.80-1.80 (m, 10H), 1.82-1.76 (m, 2H), 1.65-1.59 (m, 2H), 1.48-1.44 (m, 2H), 1.41-1.36 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 160.6, 71.7, 70.8, 70.4, 69.3, 55.2, 45.4, 40.8, 32.9, 30.0, 29.8, 27.0, 25.8. ¹¹B NMR (160 MHz, CDCl₃): δ -5.68, -7.46, -10.9, -11.6, -13.3, -15.7; IR (NaCl disc): 2926, 2856, 2604, 1686, 1519, 1276, 1216, 1114, 760 cm⁻¹; HRMS (ESI, positive) for C₁₃H₃₂B₁₀ClNO₃ (*m/z*): calculated 418.2927 (M+Na)⁺, found 418.2918.

Synthesis of 1-(2-(benzyloxy)-2-oxoethyl)-1,2-dicarba-*closo*-dodecaborane (**4**)




To a solution of *o*-carborane (757 mg, 5.25 mmol) in THF (20 mL), was added *n*-BuLi 1.6 M solution in hexane (3.28 mL, 5.25 mmol) at -78 °C. After the resulting mixture was stirred at 0 °C under argon atmosphere for 1 h, benzyl bromoacetate (784 μ L, 5.0 mmol) was added. Then, the resulting mixture was stirred at room temperature for 3 h. After that, the reaction mixture was quenched with H₂O. The mixture was extracted twice with ethyl acetate and the combined extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by column chromatography on silica gel (10% EtOAc in Hexane) afforded **6** as colorless oil (691 mg, 2.36 mmol, 47%). ¹H NMR (400 MHz, CDCl₃): δ 7.40-7.33 (m, 5H), 5.14 (s, 2H), 4.35 (s, 1H), 3.27 (s, 2H), 3.00-1.60 (m, 10H); ¹³C NMR (125 MHz, CDCl₃): δ 167.3, 134.6, 129.1, 128.1, 128.8, 67.9, 58.7, 41.7; ¹¹B NMR (160 MHz, CDCl₃): δ -2.05, -4.98, -9.23, -10.5, -12.0, -12.8; IR (NaCl disc): 2592, 1739, 1178 cm⁻¹; HRMS (ESI, positive) for C₁₁H₂₀B₁₀O₂ (*m/z*): calculated 317.2305 (M+Na)⁺, found 317.2307.

Synthesis of 1-(carboxymethyl)-1,2-dicarba-*closo*-dodecaborane (**5**)



To a solution of **4** (207 mg, 0.71 mmol) in MeOH (10 mL), was added Pd/C wetted with water (34 mg). The resulting mixture was stirred at room temperature until the full conversion of a starting material was observed. The reaction mixture was filtered on celite pad and concentrated. The resulting mixture was dissolved with aq. NaHCO₃ and washed with hexane three times. After the water layer was acidified with aq. HCl, extracted with EtOAc, dried over Na₂SO₄, filtered, and concentrated afforded **5** (123 mg, 0.61 mmol, 86%). ¹H NMR (400 MHz, CD₃CN): δ 8.93 (br, 1H), 4.64 (s, 1H), 3.28 (s, 2H), 3.10-1.40 (m, 10H). This spectrum is consistent with the reported values.⁴


Synthesis of *N*-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-1,7-dicarba-*closo*-dodecaborane-1-acetamide (**2**)



To a solution of **5** (40 mg, 0.20 mmol) in CH₂Cl₂ (1 mL), was slowly added excess amount of oxalyl chloride. After the resulting mixture was stirred at 50 °C under argon atmosphere for 12 h, the reaction mixture was concentrated under pressure. The crude materials were used to the next reaction without further purification.

To a solution of HaloTag linker **6** (44 mg, 0.20 mmol) and triethylamine (400 μL) in CH₂Cl₂ (1 mL) at 0 °C was slowly added the crude material in CH₂Cl₂ (500 μL). After the resulting mixture was stirred at 0 °C for 30 min, it was warmed up to room temperature and stirred for 1 h. The reaction mixture was quenched with 1M aq. HCl. The mixture was extracted three times with CH₂Cl₂ and the combined extracts were dried over Na₂SO₄, filtered, and concentrated. Then, the crude materials were purified by column chromatography on silica gel (70% EtOAc in Hexane) afforded **2** as a white solid (50 mg, 0.12 mmol, 62%). m.p. 38-40 °C; ¹H NMR (400 MHz, CDCl₃) δ 6.36 (bs, 1H), 4.60 (s, 1H), 3.64-3.62 (m, 2H), 3.59-3.52 (m, 6H), 3.48 (t, *J* = 6.7 Hz, 2H), 3.43 (q, *J* = 5.2 Hz, 2H), 3.04 (s, 2H), 2.80-1.60 (m, 10H), 1.81-1.75 (m, 2H), 1.64-1.59 (m, 2H), 1.50-1.44 (m, 2H), 1.40-1.36 (m, 2H). ¹³C NMR (125 MHz, CDCl₃): δ 166.3, 71.4, 70.5, 70.1, 69.3, 69.2, 58.8, 45.1, 43.5, 39.7, 32.6, 29.6, 26.8, 25.5. ¹¹B NMR (160 MHz, CDCl₃): δ -2.15, -5.17, -9.53, -10.7, -11.8, -12.7; IR (NaCl disc): 2937, 2865, 2590, 1659, 1556, 1098 cm⁻¹; HRMS (ESI, positive) for C₁₄H₃₄B₁₀ClNO₃ (m/z): calculated 432.3084 (M+Na)⁺, found 432.3073.

Synthesis of 1-((2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)ethyl)carbamoyl)-1,7-dicarba-*closo*-dodecaborane (MIC)



To a solution of **3** (270 mg, 1.43 mmol), HATU (815 mg, 2.14 mmol), and DIEA (369 mg, 2.86 mmol) in CH_2Cl_2 , was added *N*-Boc-ethylenediamine (400 mg, 2.50 mmol) and stirred for 3 h at room temperature. The mixture was washed with 1 M HCl aq., saturated NaHCO_3 aq., and Brine. The organic layer was dried over MgSO_4 , and dried up under the reduced pressure. To a solution of the resulting crude materials in CH_2Cl_2 (1.0 mL), was added 4 M HCl in dioxane (4.0 mL) at 0 °C and the mixture was stirred at room temperature for 10 h. After removal of the solvent under the reduced pressure, the residue was suspended in EtOAc and washed with saturated NaHCO_3 aq. and brine. The organic layer was dried over MgSO_4 , the solvent was removed. The crude materials were used to the next reaction without further purification.

To a solution of 4-maleimidobutyric acid (256 mg, 1.40 mmol), HATU (570 mg, 1.50 mmol), and DIEA (387 mg, 3.00 mmol) in CH_2Cl_2 was added the crude material in CH_2Cl_2 , and stirred at room temperature for 11 h. The resulting mixture was washed with 1 M HCl aq., saturated NaHCO_3 aq., and Brine. The organic layer was dried over MgSO_4 , and dried up under the reduced pressure. The crude materials were purified by column chromatography on silica gel (20% EtOAc in Hexane) afforded **MIC** as a white solid (204 mg, 0.516 mmol, 36% 3 steps). m.p. 48-50 °C; ^1H NMR (500 MHz; CDCl_3) δ 7.09 (s, 1H), 6.73 (s, 2H), 6.39 (s, 1H), 3.58 (t, J = 6.5 Hz, 2H), 3.33-3.38 (m, 4H), 3.05 (s, 1H), 2.17 (t, J = 7.0 Hz, 2H), 1.94 (quin, J = 6.5 Hz, 2H). ^{13}C NMR (125 MHz; CDCl_3) δ 173.2, 171.0, 161.18, 134.2, 75.45, 42.10, 38.82, 36.93, 33.08, 24.60. ^{11}B NMR (160 MHz; CDCl_3) δ -5.63, -7.46, -10.87, -11.57, -13.27, -15.73; IR (NaCl disc): 3343, 3062, 2939, 2604, 1706. HRMS (ESI, positive) for $\text{C}_{13}\text{H}_{25}\text{B}_{10}\text{N}_3\text{O}_4$ (m/z): calculated 420.2690 ($\text{M}+\text{Na}$) $^+$; found 420.2688.




Figure S1. Flow cytometric analysis of HA–HaloTag2-EGFP levels in Flp-In 293 cells treated with HyT13 and compounds **1** and **2**.

Table S1 Condition of electroporation for FITC-BSA

Condition ^a	Voltage [V]	Pulse length [ms]	Interval [ms]	Number	Decay rate [%]	Polarity
1	150	10	50	5	20	+
2	150	20	50	5	20	+
3	150	10	50	1	20	+
4	150	30	50	5	20	+
5	150	10	50	5	10	+
6	150	20	50	5	10	+

^aCondition for poring pulse. Condition for transfer pulse was constant as follows: transfer pulse; pulse voltage, 20 V; pulse length, 50 ms; pulse interval, 50 ms; pulse number, 20; decay rate, 30; polarity, +/-.




Figure S2 (a) Histograms of LNCaP cells in which FITC-BSA (1 mg/mL) was treated for 24 h and electroporated under various condition (Table S1). (b) Mean fluorescence intensity of FITC-BSA internalized into LNCaP, the ratio of dead cells (PI positive).




Figure S3 BSA/ β -actin values in LNCaP cells electroporated with unmodified BSA, MIC-BSA(3/1), and MIC-BSA(10/1).




Figure S4 Stability experiments of compounds **1** and **2** in DMSO/H₂O (3/1) monitored by ¹¹B NMR spectroscopy (160 MHz, DMSO-d₆) for 24 h.⁵ The *m*-carborane derivative **1** was very stable, whereas the *o*-carborane derivative **2** was slightly deboronized (-33 and -37 ppm) in a time-dependent manner (up to 24h).


3. Reference

- (1) Neklesa, T. K.; Tae, H. S.; Schneekloth, A. R.; Stulberg, M. J.; Corson, T. W.; Sundberg, T. B.; Raina, K.; Holley, S. A.; Crews, C. M., Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins. *Nat. Chem. Biol.* **2011**, *7* (8), 538–543.
- (2) Tae, H. S.; Sundberg, T. B.; Neklesa, T. K.; Noblin, D. J.; Gustafson, J. L.; Roth, A. G.; Raina, K.; Crews, C. M., Identification of hydrophobic tags for the degradation of stabilized proteins. *ChemBioChem* **2012**, *13* (4), 538–541.
- (3) Scholz, M.; Blobaum, A. L.; Marnett, L. J.; Hey-Hawkins, E., *ortho*-Carbaborane Derivatives of Indomethacin as Cyclooxygenase (COX)-2 Selective Inhibitors. *Bioorganic Med. Chem.* **2012**, *20* (15), 4830–4837.
- (4) Brozek, E. M.; Mollard, A. H.; Zharov, I., Silica nanoparticles carrying boron-containing polymer brushes. *J. Nanoparticle Res.* **2014**, *16* (4), 2407.
- (5) Neumann, W.; Xu, S.; Sárosi, M. B.; Scholz, M. S.; Crews, B. C.; Ghebreselasie, K.; Banerjee, S.; Marnett, L. J.; Hey-Hawkins, E. Nido-Dicarbaborate Induces Potent and Selective Inhibition of Cyclooxygenase-2. *ChemMedChem* **2016**, *11* (2), 175–178.


4. Spectra data

N-(2-(2-((6-chlorohexyl)oxy)ethoxy)ethyl)-1,7-dicarba-*clos*o-dodecaborane-1-carboxamide (3)


^1H NMR (400 MHz, CDCl_3) (1)



^{11}B NMR (160 MHz, CDCl_3)




^{13}C NMR (125 MHz, CDCl_3) (1)




1-(2-(benzyloxy)-2-oxoethyl)-1,2-dicarba-*closo*-dodecaborane (4)


^1H NMR (400 MHz, CDCl_3) (4)



^{11}B NMR (160 MHz, CDCl_3) (4)




^{13}C NMR (125 MHz, CDCl_3) (4)




***N*-(2-(2-(((6-chlorohexyl)oxy)ethoxy)ethyl)-1,7-dicarba-*closo*-dodecaborane-1- acetamide (2)**


¹H NMR (400 MHz, CDCl₃) (2)



¹¹B NMR (160 MHz, CDCl₃) (2)




^{13}C NMR (125 MHz, CDCl_3) (2)



1-((2-(4-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)butanamido)ethyl)carbamoyl)-1,7-dicarba-*closo*-dodecaborane (MIC)

^1H NMR (400 MHz, CDCl_3)



^{11}B NMR (160 MHz, CDCl_3) (**MIC**)

